MCID: PNS012
MIFTS: 60

Paine Syndrome

Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Paine Syndrome

MalaCards integrated aliases for Paine Syndrome:

Name: Paine Syndrome 58 54 74
Pain Disorder 12 56 15 74
Pain 6 44 17
Microcephaly with Spastic Diplegia 58 54
Pain Syndrome 15

Characteristics:

OMIM:

58
Inheritance:
x-linked


HPO:

33
paine syndrome:
Inheritance x-linked inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0060164
OMIM 58 311400
ICD10 34 R52 R52.9
MedGen 43 C1412041

Summaries for Paine Syndrome

MedlinePlus : 44 Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Paine Syndrome, also known as pain disorder, is related to familial episodic pain syndrome and complex regional pain syndrome. An important gene associated with Paine Syndrome is PTPRQ (Protein Tyrosine Phosphatase Receptor Type Q), and among its related pathways/superpathways are Development Endothelin-1/EDNRA signaling and Neuropathic Pain-Signaling in Dorsal Horn Neurons. The drugs Acetaminophen and Dinoprostone have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and brain, and related phenotypes are microcephaly and generalized myoclonic seizures

Disease Ontology : 12 A somatoform disorder that involves chronic pain in one or more areas, and is thought to be caused by psychological stress.

Description from OMIM: 311400

Related Diseases for Paine Syndrome

Diseases in the Paine Syndrome family:

Central Pain Syndrome Pain - Chronic

Diseases related to Paine Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2800)
# Related Disease Score Top Affiliating Genes
1 familial episodic pain syndrome 34.1 SCN11A TRPA1
2 complex regional pain syndrome 33.9 IL1B SCN9A TAC1
3 indifference to pain, congenital, autosomal recessive 33.9 SCN10A SCN11A SCN9A
4 interstitial cystitis 33.2 NGF TAC1 TRPV1
5 causalgia 32.6 NGF SCN10A SCN11A TAC1
6 esophagitis, eosinophilic, 1 31.8 ATP12A ATP4A
7 neuroschistosomiasis 31.7 NGF TAC1
8 prurigo nodularis 31.7 NGF TAC1
9 hernia, hiatus 31.6 ATP12A ATP4A
10 lateral medullary syndrome 31.6 ATP12A ATP4A
11 peripheral nervous system disease 31.5 NGF SCN9A TAC1 TRPV1
12 superior mesenteric artery syndrome 31.4 ATP12A ATP4A
13 lymphocytic colitis 31.4 ATP12A ATP4A
14 paroxysmal extreme pain disorder 31.3 SCN10A SCN11A SCN9A TRPV1
15 cystitis 31.3 NGF TAC1 TRPV1
16 autonomic nervous system disease 31.3 NGF TAC1
17 esophageal candidiasis 31.2 ATP12A ATP4A
18 laryngitis 31.0 ATP12A ATP4A IL1B
19 toxic megacolon 30.9 ATP12A ATP4A
20 rumination disorder 30.9 ATP12A ATP4A
21 lesion of sciatic nerve 30.7 NGF SCN10A TRPV1
22 polyposis, skin pigmentation, alopecia, and fingernail changes 30.7 ATP12A ATP4A CABIN1
23 jejunoileitis 30.2 NGF IL1B ATP4A ATP12A
24 trigeminal neuralgia 29.8 SCN10A SCN9A TRPV1
25 dyskinesia of esophagus 29.8 ATP12A ATP4A
26 chronic intestinal vascular insufficiency 29.7 ATP12A ATP4A
27 esophageal disease 29.7 ATP12A ATP4A TRPV1
28 duodenitis 29.7 ATP12A ATP4A
29 stomach disease 29.7 TRPV1 SCN10A IL1B ATP4A ATP12A
30 bile reflux 29.7 ATP12A ATP4A
31 erythromelalgia 29.6 SCN10A SCN9A
32 sciatic neuropathy 29.6 NGF SCN10A TRPV1
33 erythermalgia, primary 29.6 SCN10A SCN11A SCN9A
34 active peptic ulcer disease 29.6 ATP12A ATP4A
35 mononeuropathy 29.5 TAC1 TRPV1
36 diabetic neuropathy 29.5 NGF SCN9A TRPV1
37 burning mouth syndrome 29.4 TRPV1 TAC1 SCN9A NGF
38 corneal ulcer 29.4 IL1B NGF
39 migraine with or without aura 1 29.3 TAC1 TRPA1 TRPV1
40 pneumatosis cystoides intestinalis 29.3 ATP12A ATP4A
41 neuroma 29.2 NGF SCN10A TRPV1
42 laryngeal tuberculosis 29.2 ATP12A ATP4A
43 eosinophilic gastritis 29.2 ATP12A ATP4A
44 peptic ulcer perforation 29.0 ATP12A ATP4A
45 peptic esophagitis 29.0 ATP12A ATP4A IL1B
46 clostridium difficile colitis 29.0 ATP12A ATP4A IL1B
47 gastrointestinal system disease 28.9 ATP12A ATP4A IL1B TRPV1
48 ischemic neuropathy 28.8 ATP12A ATP4A NGF CABIN1
49 somatoform disorder 28.1 CABIN1 IL1B NGF SCN9A TAC1 TRPA1
50 insensitivity to pain, congenital, with anhidrosis 12.5

Graphical network of the top 20 diseases related to Paine Syndrome:



Diseases related to Paine Syndrome

Symptoms & Phenotypes for Paine Syndrome

Human phenotypes related to Paine Syndrome:

33
# Description HPO Frequency HPO Source Accession
1 microcephaly 33 HP:0000252
2 generalized myoclonic seizures 33 HP:0002123
3 spastic diplegia 33 HP:0001264
4 olivopontocerebellar hypoplasia 33 HP:0006955

Symptoms via clinical synopsis from OMIM:

58
Head:
microcephaly
hypoplasia of cerebellum, inferior olives and pons

Lab:
variable elevated spinal fluid amino acids

Neuro:
spastic diplegia
myoclonic seizures
absent abdominal reflexes

Clinical features from OMIM:

311400

MGI Mouse Phenotypes related to Paine Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 INPP5D NGF PTPRQ SCN10A SCN11A SCN9A
2 integument MP:0010771 9.61 IL1B INPP5D NGF SCN10A SCN11A SCN9A
3 taste/olfaction MP:0005394 8.8 SCN9A TRPA1 TRPV1

Drugs & Therapeutics for Paine Syndrome

Drugs for Paine Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 535)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 103-90-2 1983
2
Dinoprostone Approved Phase 4 363-24-6 5280360
3
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 51-45-6 774
4
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
5
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 60142-96-3 3446
6
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
7
Naltrexone Approved, Investigational, Vet_approved Phase 4,Not Applicable 16590-41-3 5360515
8
Ethanol Approved Phase 4,Phase 3,Not Applicable 64-17-5 702
9
Benzocaine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
10
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-41-2 439260
11
Levomilnacipran Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 96847-54-0
12
tannic acid Approved Phase 4,Phase 1,Phase 2,Not Applicable 1401-55-4
13
Milnacipran Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 92623-85-3 65833
14
Etoricoxib Approved, Investigational Phase 4,Phase 2 202409-33-4 123619
15
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 303-53-7 2895
16
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-48-6 2160
17
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
18
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 175805 71273
19
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 38396-39-3, 2180-92-9 2474
20
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 124-94-7 31307
21
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-84-3 187
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
24
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 62-31-7, 51-61-6 681
25
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 27203-92-5 33741
26
Perphenazine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-39-9 4748
27
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
28
Glycerol Approved, Investigational Phase 4,Phase 2 56-81-5 753
29
Cycloserine Approved Phase 4 68-41-7 6234 401
30
Colchicine Approved Phase 4 64-86-8 2833 6167
31
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 5311068 68602
32
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
33
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
34
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 6740-88-1 3821
35
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Not Applicable 15307-86-5 3033
36
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
37
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
38
Saw palmetto Approved, Experimental, Investigational Phase 4
39
Trazodone Approved, Investigational Phase 4,Phase 2 19794-93-5 5533
40
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
41
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
42
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
43
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
44
Paroxetine Approved, Investigational Phase 4,Phase 1,Phase 2 61869-08-7 43815
45
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
46
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 378-44-9 9782
47
Metoprolol Approved, Investigational Phase 4,Not Applicable 37350-58-6, 51384-51-1 4171
48
Petrolatum Approved, Investigational Phase 4,Not Applicable 8009-03-8
49
Sodium Citrate Approved, Investigational Phase 4,Phase 3 68-04-2
50
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 76-42-6 5284603

Interventional clinical trials:

(show top 50) (show all 1430)
# Name Status NCT ID Phase Drugs
1 Close Kinect Chain Exercise With Kinesio Taping in the Management of Patellofemoral Pain Syndrome Unknown status NCT02241148 Phase 4 Acetaminophen 500mg
2 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
3 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
4 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? Unknown status NCT02806440 Phase 4 Low dose naltrexone;Placebo
5 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4 Milnacipran
6 Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia Unknown status NCT00755521 Phase 4 etoricoxib
7 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
8 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
9 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. Completed NCT01250184 Phase 4 Lidocaine injection
10 EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes Completed NCT00272532 Phase 4 Thiocolchicoside
11 Cortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study Completed NCT02639039 Phase 4 Cortisone Injection
12 Effects of Dexmedetomidine Used in Continuous Thoracic Paravertebral Blocks Completed NCT02619513 Phase 4 Dexmedetomidine;Ropivacaine
13 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4 lansoprazole;mosapride
14 Prophylactic Administration of Vitamin C in Wrist Fractures Completed NCT00296868 Phase 4 ascorbic acid (vitamin C) versus placebo
15 Pregabalin and Post-thoracotomy Pain Completed NCT00663962 Phase 4 Pregabalin;Placebo
16 Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain Completed NCT01067456 Phase 4
17 Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome Completed NCT03291197 Phase 4 Suprascapular and median nerve blocks
18 Restore Claims Characterization Study Completed NCT00200122 Phase 4
19 Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome Completed NCT00241215 Phase 4 Botulinum toxin serotype A
20 Combined Intra-articular Shoulder Injection and Stellate Ganglion Block in Chronic Post-mastectomy Shoulder Pain Completed NCT03586154 Phase 4 ketamine and bupivacaine injection
21 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
22 Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Completed NCT01495806 Phase 4 Glucomannan;placebo
23 Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain Completed NCT03241602 Phase 4 Intraperitoneal lidocaine
24 High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System Completed NCT02265848 Phase 4
25 Efficacy of Gabapentin in the Treatment of Chest Pain and Paresthesia in Patients With Sternotomy Completed NCT00800527 Phase 4 Gabapentin;Diclofenac
26 The Efficacy and Safety of Qizhiweitong Granule on Patients With Functional Dyspepsia in a Multi-center Clinical Study Completed NCT02460601 Phase 4 Qizhiweitong granule
27 Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain Completed NCT02024724 Phase 4 Bupivacaine;Triamcinolone;Dexamethasone
28 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis Completed NCT00919802 Phase 4 Oxytocin
29 Bupivacaine Versus Lidocaine Local Anesthesia Completed NCT01751347 Phase 4 Bupivacaine;Lidocaine
30 Imaging Pain Relief in Osteoarthritis Completed NCT02208778 Phase 4 Duloxetine;Remifentanil;Placebo (for Remifentanil);Placebo (for Duloxetine)
31 Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis Completed NCT01195116 Phase 4 Dexmedetomidine;Normal Saline
32 Treatment of Chronic Bacterial Prostatitis Completed NCT02130713 Phase 4 Third generation fluoroquinolone
33 Discomfort and Psychosocial Difficulties in Fibromyalgia Completed NCT02078791 Phase 4 Botox infiltration
34 Strengthening Exercises for Fibromyalgia Completed NCT02063750 Phase 4
35 Heart Rate Variability in Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
36 Quetiapine Compared With Placebo in the Management of Fibromyalgia Completed NCT01458964 Phase 4 Quetiapine
37 Effect of Milnacipran on Pain in Fibromyalgia Completed NCT01288807 Phase 4 Milnacipram
38 Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia Completed NCT01226667 Phase 4 Pregabalin
39 A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia Completed NCT01173055 Phase 4 milnacipran;Placebo
40 Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia Completed NCT01077375 Phase 4 Placebo;Milnacipran
41 Drug and Talk Therapy for Fibromyalgia Completed NCT01038323 Phase 4 Educational with milnacipran
42 Pregabalin In Adolescent Patients With Fibromyalgia Completed NCT01020526 Phase 4 pregabalin
43 Adolescent Fibromyalgia Study Completed NCT01020474 Phase 4 placebo;pregabalin (Lyrica)
44 Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia Completed NCT01014585 Phase 4 Placebo;Milnacipran
45 Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study Completed NCT00983320 Phase 4 quetiapine;placebo
46 A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia Completed NCT00965601 Phase 4
47 A Study for Adult Patients With Fibromyalgia Completed NCT00965081 Phase 4 Duloxetine;Placebo
48 Trazodone and Its Augmentation With Pregabalin in the Treatment of Fibromyalgia Completed NCT00791739 Phase 4 trazodone, pregabalin
49 An Efficacy Study of Combination of Tramadol and Acetaminophen Tablets in the Treatment of Participants With Fibromyalgia Pain Completed NCT00766675 Phase 4 Tramadol hydrochloride;Acetaminophen
50 Comparative Efficacy and Tolerability of Quetiapine XR and Amitriptyline in the Treatment of Fibromyalgia Completed NCT00766350 Phase 4 amitriptyline;quetiapine

Search NIH Clinical Center for Paine Syndrome

Genetic Tests for Paine Syndrome

Anatomical Context for Paine Syndrome

MalaCards organs/tissues related to Paine Syndrome:

42
Prostate, Bone, Brain, Spinal Cord, Kidney, Thyroid, Endothelial

Publications for Paine Syndrome

Articles related to Paine Syndrome:

(show top 50) (show all 152)
# Title Authors Year
1
The role of coping with negative emotions in cognitive behavioral therapy for persistent somatoform pain disorder: is it more important than pain catastrophizing? ( 31102312 )
2019
2
Reduced empathic pain processing in patients with somatoform pain disorder: Evidence from behavioral and neurophysiological measures. ( 30878486 )
2019
3
Development and preliminary evaluation of a new screening instrument for atypical odontalgia and persistent dentoalveolar pain disorder. ( 30229950 )
2019
4
Granulocyte-macrophage colony-stimulating factor receptor expression in clinical pain disorder tissues and role in neuronal sensitization. ( 30534627 )
2018
5
The Effectiveness of High-frequency Repetitive Transcranial Magnetic Stimulation in Persistent Somatoform Pain Disorder: A Case Series. ( 30083490 )
2018
6
Cortical Thickness Alterations in Chronic Pain Disorder: An Exploratory MRI Study. ( 29787468 )
2018
7
Processing of Emotional Faces in Patients with Chronic Pain Disorder: An Eye-Tracking Study. ( 29556205 )
2018
8
Bee Stings and Chronic Pain Disorder. ( 29545983 )
2018
9
Comparison of pain, disorder, back performance, and psychological factors in patients with low back pain and radicular pain. ( 29410582 )
2018
10
Persistent Dentoalveolar Pain Disorder: A Comprehensive Review. ( 29174443 )
2018
11
Treatment for Persistent Somatoform Pain Disorder via Electroacupuncture and a Low Dosage of Fluoxetine Hydrochloride. ( 30881254 )
2017
12
Insecure attachment style and cumulative traumatic life events in patients with somatoform pain disorder: A cross-sectional study. ( 29167050 )
2017
13
Somatoform Pain Disorder Presenting as "Atypical Facial Pain:" A Rare Presentation in a 13-year-old. ( 28852247 )
2017
14
Use of the Central Sensitization Inventory (CSI) as a treatment outcome measure for patients with chronic spinal pain disorder in a functional restoration program. ( 28619687 )
2017
15
Decreased prefrontal brain activation during verbal fluency task in patients with somatoform pain disorder: An exploratory multi-channel near-infrared spectroscopy study. ( 28499896 )
2017
16
Altered resting-state intra- and inter- network functional connectivity in patients with persistent somatoform pain disorder. ( 28453543 )
2017
17
The Fear-Avoidance Components Scale (FACS): Responsiveness to Functional Restoration Treatment in a Chronic Musculoskeletal Pain Disorder (CMPD) Population. ( 28328697 )
2017
18
Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: An observational study. ( 28272220 )
2017
19
Parental Protectiveness Mediates the Association between Parent-Perceived Child Self-Efficacy and Health Outcomes in Pediatric Functional Abdominal Pain Disorder. ( 27657151 )
2016
20
Altered Neural Correlates of Emotion Associated Pain Processing in Persistent Somatoform Pain Disorder: An fMRI Study. ( 27641732 )
2016
21
Low Level Laser Therapy Versus Pharmacotherapy in Improving Myofascial Pain Disorder Syndrome. ( 27330698 )
2016
22
Altered Spontaneous Activity in Patients with Persistent Somatoform Pain Disorder Revealed by Regional Homogeneity. ( 26977802 )
2016
23
Psychophysiological decoupling in alexithymic pain disorder patients. ( 26804974 )
2016
24
Advanced Genetic Testing Comes to the Pain Clinic to Make a Diagnosis of Paroxysmal Extreme Pain Disorder. ( 27525141 )
2016
25
Effectiveness of group cognitive behavioral therapy for somatoform pain disorder patients in Japan: A preliminary non-case-control study. ( 26129835 )
2015
26
Psychogenic Pain Disorder--Differential Diagnosis and Treatment. ( 26529858 )
2015
27
Effects of Kamishoyosan, a Traditional Japanese Kampo Medicine, on Pain Conditions in Patients with Intractable Persistent Dentoalveolar Pain Disorder. ( 26495024 )
2015
28
Amplified Brain Processing of Dentoalveolar Pressure Stimulus in Persistent Dentoalveolar Pain Disorder Patients. ( 26485382 )
2015
29
Hypnotherapy of a pain disorder: a clinical case study. ( 25719524 )
2015
30
Bilateral congenital corneal anesthesia in a patient with SCN9A mutation, confirmed primary erythromelalgia, and paroxysmal extreme pain disorder. ( 26486037 )
2015
31
Short-lasting unilateral neuralgiform headache attacks with ispilateral facial flushing is a new variant of paroxysmal extreme pain disorder. ( 25903274 )
2015
32
p.L1612P, a novel voltage-gated sodium channel Nav1.7 mutation inducing a cold sensitive paroxysmal extreme pain disorder. ( 25285947 )
2015
33
What are the treatment options for paroxysmal extreme pain disorder? ( 26059255 )
2015
34
Prevalence of restless legs syndrome in somatoform pain disorder and its effect on quality of life. ( 25883472 )
2015
35
Healthcare pathway and biopsychosocial impact of persistent dentoalveolar pain disorder: a qualitative study. ( 24697333 )
2014
36
Pain as a late emotional reaction. Clinical research evaluating the psychosocial expression of pain disorder in preoperative and postoperative period. ( 25341289 )
2014
37
Distinctive spontaneous regional neural activity in patients with somatoform pain disorder: a preliminary resting-state fMRI study. ( 24439113 )
2014
38
Factors influencing quality of life in Chinese patients with persistent somatoform pain disorder. ( 24428222 )
2014
39
Facial affect perception and mentalizing abilities in female patients with persistent somatoform pain disorder. ( 24395204 )
2014
40
Effectiveness of a multimodal treatment program for somatoform pain disorder. ( 24305036 )
2014
41
An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder. ( 23893323 )
2014
42
Self-management is key to fibromyalgia treatment. Treating this common chronic pain disorder has baffled patients and physicians for years. ( 25029737 )
2014
43
A comparison of schemas, schema modes and childhood traumas in obsessive-compulsive disorder, chronic pain disorder and eating disorders. ( 23689753 )
2014
44
Painful micturition in a small child: an unusual clinical picture of paroxysmal extreme pain disorder. ( 24817410 )
2014
45
Distinctive neural responses to pain stimuli during induced sadness in patients with somatoform pain disorder: An fMRI study. ( 24179828 )
2013
46
The trade-off between costs and quality of care in the treatment of psychosomatic patients with somatoform pain disorder. ( 23852985 )
2013
47
Predicting return to work following treatment of chronic pain disorder. ( 23503298 )
2013
48
Frequency shifts in the anterior default mode network and the salience network in chronic pain disorder. ( 23497482 )
2013
49
Neural correlates of deficits in pain-related affective meaning construction in patients with chronic pain disorder. ( 23362496 )
2013
50
Alexithymic and somatisation scores in patients with temporomandibular pain disorder correlate with deficits in facial emotion recognition. ( 23137311 )
2013

Variations for Paine Syndrome

ClinVar genetic disease variations for Paine Syndrome:

6 (show all 16)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTPRQ NM_001145026.1(PTPRQ): c.6475C> T (p.Arg2159Ter) single nucleotide variant Pathogenic rs1445287184 GRCh38 Chromosome 12, 80670365: 80670365
2 PTPRQ NM_001145026.1(PTPRQ): c.6475C> T (p.Arg2159Ter) single nucleotide variant Pathogenic rs1445287184 GRCh37 Chromosome 12, 81064144: 81064144
3 COL5A1 NM_000093.4(COL5A1): c.608G> T (p.Gly203Val) single nucleotide variant Likely pathogenic rs1554781700 GRCh38 Chromosome 9, 134701287: 134701287
4 COL5A1 NM_000093.4(COL5A1): c.608G> T (p.Gly203Val) single nucleotide variant Likely pathogenic rs1554781700 GRCh37 Chromosome 9, 137593133: 137593133
5 GJB1 NM_001097642.2(GJB1): c.109G> T (p.Val37Leu) single nucleotide variant Likely pathogenic rs1057518946 GRCh38 Chromosome X, 71223816: 71223816
6 GJB1 NM_001097642.2(GJB1): c.109G> T (p.Val37Leu) single nucleotide variant Likely pathogenic rs1057518946 GRCh37 Chromosome X, 70443666: 70443666
7 SCN4A NM_000334.4(SCN4A): c.1333G> T (p.Val445Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs121908552 GRCh38 Chromosome 17, 63964587: 63964587
8 SCN4A NM_000334.4(SCN4A): c.1333G> T (p.Val445Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs121908552 GRCh37 Chromosome 17, 62041947: 62041947
9 OAT NM_000274.3(OAT): c.875A> G (p.Lys292Arg) single nucleotide variant Likely pathogenic rs1057518927 GRCh37 Chromosome 10, 126091521: 126091521
10 OAT NM_000274.3(OAT): c.875A> G (p.Lys292Arg) single nucleotide variant Likely pathogenic rs1057518927 GRCh38 Chromosome 10, 124402952: 124402952
11 SELENON NM_020451.2(SELENON): c.482G> A (p.Arg161Gln) single nucleotide variant Uncertain significance rs765749301 GRCh37 Chromosome 1, 26131711: 26131711
12 SELENON NM_020451.2(SELENON): c.482G> A (p.Arg161Gln) single nucleotide variant Uncertain significance rs765749301 GRCh38 Chromosome 1, 25805220: 25805220
13 KIF1B NM_015074.3(KIF1B): c.2473G> A (p.Glu825Lys) single nucleotide variant Uncertain significance rs763122049 GRCh38 Chromosome 1, 10324831: 10324831
14 KIF1B NM_015074.3(KIF1B): c.2473G> A (p.Glu825Lys) single nucleotide variant Uncertain significance rs763122049 GRCh37 Chromosome 1, 10384889: 10384889
15 MAP2K2 NM_030662.3(MAP2K2): c.514A> G (p.Lys172Glu) single nucleotide variant Uncertain significance rs1413580671 GRCh38 Chromosome 19, 4102390: 4102390
16 MAP2K2 NM_030662.3(MAP2K2): c.514A> G (p.Lys172Glu) single nucleotide variant Uncertain significance rs1413580671 GRCh37 Chromosome 19, 4102388: 4102388

Expression for Paine Syndrome

Search GEO for disease gene expression data for Paine Syndrome.

Pathways for Paine Syndrome

Pathways related to Paine Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.32 IL1B NGF TRPA1 TRPV1
2
Show member pathways
12.3 SCN10A SCN11A SCN9A TAC1
3 12.16 NGF SCN10A SCN11A SCN9A
4
Show member pathways
12.08 ATP12A ATP4A SCN10A SCN11A SCN9A
5
Show member pathways
12.05 ATP12A ATP4A TRPA1 TRPV1
6 11.87 IL1B NGF TAC1
7
Show member pathways
11.64 SCN10A SCN11A SCN9A
8
Show member pathways
11.21 SCN10A SCN11A SCN9A
9 11 NGF TRPV1
10 10.85 TRPA1 TRPV1
11 10.28 SCN10A SCN11A SCN9A

GO Terms for Paine Syndrome

Cellular components related to Paine Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.35 NGF SCN10A SCN11A SCN9A TAC1
2 stereocilium bundle GO:0032421 9.16 PTPRQ TRPA1
3 voltage-gated sodium channel complex GO:0001518 8.8 SCN10A SCN11A SCN9A

Biological processes related to Paine Syndrome according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.89 SCN10A SCN11A SCN9A TRPA1 TRPV1
2 inflammatory response GO:0006954 9.88 IL1B SCN9A TAC1 TRPV1
3 ion transmembrane transport GO:0034220 9.81 SCN10A SCN9A TRPA1 TRPV1
4 regulation of ion transmembrane transport GO:0034765 9.76 SCN10A SCN11A SCN9A
5 ion transport GO:0006811 9.7 ATP12A ATP4A SCN10A SCN11A SCN9A TRPA1
6 sodium ion transmembrane transport GO:0035725 9.65 SCN10A SCN11A SCN9A
7 ATP hydrolysis coupled proton transport GO:0015991 9.6 ATP12A ATP4A
8 positive regulation of cytosolic calcium ion concentration GO:0007204 9.59 TAC1 TRPV1
9 cellular sodium ion homeostasis GO:0006883 9.57 ATP12A ATP4A
10 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.56 ATP12A ATP4A
11 cellular potassium ion homeostasis GO:0030007 9.55 ATP12A ATP4A
12 sodium ion export across plasma membrane GO:0036376 9.54 ATP12A ATP4A
13 neuronal action potential GO:0019228 9.54 SCN10A SCN11A SCN9A
14 behavioral response to pain GO:0048266 9.52 SCN9A TRPV1
15 response to pain GO:0048265 9.5 TAC1 TRPA1 TRPV1
16 detection of chemical stimulus involved in sensory perception of pain GO:0050968 9.46 TRPA1 TRPV1
17 fever generation GO:0001660 9.43 TRPV1 IL1B
18 membrane depolarization during action potential GO:0086010 9.43 SCN10A SCN11A SCN9A
19 thermoception GO:0050955 9.4 TRPA1 TRPV1
20 response to morphine GO:0043278 9.3 TAC1
21 sodium ion transport GO:0006814 9.13 SCN10A SCN11A SCN9A
22 sensory perception of pain GO:0019233 9.02 TRPV1 TRPA1 SCN9A SCN10A TAC1

Molecular functions related to Paine Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated ion channel activity GO:0005244 9.58 SCN10A SCN11A SCN9A
2 ion channel activity GO:0005216 9.56 SCN10A SCN11A SCN9A TRPV1
3 calcium-release channel activity GO:0015278 9.37 TRPA1 TRPV1
4 sodium:potassium-exchanging ATPase activity GO:0005391 9.32 ATP12A ATP4A
5 potassium:proton exchanging ATPase activity GO:0008900 9.16 ATP12A ATP4A
6 sodium channel activity GO:0005272 9.13 SCN10A SCN11A SCN9A
7 voltage-gated sodium channel activity GO:0005248 8.8 SCN10A SCN11A SCN9A

Sources for Paine Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....